Y chromosome loss links to diabetes—but only in some men

A new study in Nature Medicine has uncovered a surprising genetic risk factor for type 2 diabetes: the somatic loss of the Y chromosome (LOY) in men. Researchers found that East Asian men with LOY in their pancreatic β-cells faced a higher risk of developing diabetes—but only when their polygenic risk scores were low. This counterintuitive interaction suggests LOY doesn’t act alone but rather amplifies existing vulnerabilities.

The study analyzed genetic data from East Asian and European populations, confirming LOY’s association with diabetes in the former group. Crucially, the effect vanished in men with high polygenic risk, implying LOY’s role is context-dependent. The discovery of LOY in pancreatic cells—critical for insulin production—adds biological plausibility to the link, though causality remains unproven.

This isn’t the first time LOY has been tied to disease. Prior research linked it to Alzheimer’s and cancer, but its diabetes connection is newer. The study’s observational nature means it can’t determine whether LOY causes diabetes or merely correlates with other aging-related changes.

The findings arrive with important caveats. The study’s sample size for East Asian men was robust, but European populations showed no significant effect—a reminder that genetic risk factors often vary by ancestry. LOY also becomes more common with age, raising questions about whether it’s a marker of broader cellular aging rather than a direct diabetes trigger.

For patients, the news changes little. LOY isn’t yet measurable in routine clinical settings, and even if it were, the study offers no intervention. The American Diabetes Association still emphasizes lifestyle and polygenic screening as primary tools for risk assessment. Researchers stress that LOY’s role—while biologically intriguing—remains a research-stage observation, not a diagnostic or therapeutic target.

The study’s real value may lie in its methodological rigor. By combining somatic mutations with polygenic scores, it highlights how layered genetic risks interact. Future work could explore whether LOY accelerates β-cell dysfunction or simply reflects it—a distinction with major implications for drug development.